CERC News and Press, Cerecor Inc. From 02/24/21

Today, we check back in on a developmental firm called Cerecor that is focused on developing treatments for rare pediatric and orphan diseases. This is the first revisit in the last 11 months. The company seems to be advancing its pipeline and recently did a capital raise to address f...

ROCKVILLE, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has grant...

Are These 5 Cheap Biotech Penny Stocks Worth It? With only a week or so left in January, penny stocks remain a hot item in the market. As an investor, it’s important to monitor certain trends. Right now could the time to find some biotech penny stocks to watch. Many of th...

Cerecor ([[CERC]] -1.0%) announces exercise by the underwriters of their option to purchase an additional 1,648,812 shares at a price to the public of $2.60/share.This increases the total offered through the previously announced underwritten public offering to 13,971,819 of common stock and 1...

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (“Cerecor”; NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today t...

Armistice Capital, holder of 10% shares of Cerecor (CERC) adds 2.5M common shares to its existing holding for the total transaction value of $6.5M.Post share acquisition, Capital direct holding is 32.6M.Shares +6% in premarket.Press ReleasePreviously (Jan. 8): Cerecor prices $36.4M ...

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today the closing of the previou...

Sarepta Therapeutics (SRPT) -48% as DMD gene therapy treatment fails to meet primary endpoint.Neoleukin Therapeutics (NLTX) -19% after receiving clinical hold letter from FDA related to CMC assay development for NL-201.Solid Biosciences (SLDB) -18% after Sarepta ...

Cerecor (CERC) inks agreement with Jefferies under which the underwriters have agreed to purchase, on a firm commitment basis, ~12.3M common shares at $2.60/share.In addition, the Company is offering pre-funded warrants to purchase up to ~1.7M common shares at $2.599/warrant.Expected gross pr...

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it has entered into a...